Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 11/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | EYA3 | Q99504 | 4/20 | 0.43 |
| ▸ | TTR | P02766 | 4/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | EYA2 | O00167 | 1/20 | 0.41 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.41 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20717980 | 0.86 | SLC22A12 (0.49) | SLC22A12CYP2C19EYA3TTRCYP2C9 | |
| SCHEMBL20718307 | 0.86 | SLC22A12 (0.49) | SLC22A12CYP2C19EYA3TTRCYP2C9 | |
| SCHEMBL25892402 | 0.81 | CYP2C19 (0.67) | SLC22A12CYP2C19EYA3TTRCYP2C9 | |
| SCHEMBL20718354 | 0.81 | CYP2C19 (0.39) | SLC22A12CYP2C19EYA3TTRCYP2C9 | |
| SCHEMBL20718558 | 0.81 | CYP2C19 (0.39) | SLC22A12CYP2C19EYA3TTRCYP2C9 | |
| SCHEMBL20718462 | 0.78 | EYA3 (0.54) | SLC22A12CYP2C19EYA3TTRCYP2C9 | |
| SCHEMBL20718355 | 0.76 | SLC22A12 (0.39) | SLC22A12CYP2C19EYA3TTRCYP2C9 | |
| SCHEMBL20280646 | 0.68 | CYP2C19 (0.65) | SLC22A12CYP2C19EYA3TTRCYP2C9 | |
| SCHEMBL20280676 | 0.65 | SLC22A12 (0.75) | SLC22A12CYP2C19EYA3TTRCYP2C9 | |
| SCHEMBL20718305 | 0.64 | EYA3 (0.58) | SLC22A12CYP2C19EYA3TTRCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227419-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20220112171-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. | 2022-04-14 | — | — | US | disclosed |
| US-11236058-B2 | Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia | ARTHROSI THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200148659-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20190169150-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
| US-10239854-B2 | Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia | ARTHROSI THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20190040030-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236058-B2 | Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia | SLC10A1, UGT1A1, UGT1A3 | SLC22A12 71/4885CYP2C19 48/4885EYA3 4188/4885 |
| US-20190169150-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | SLC10A1, UGT1A1, UGT1A3 | SLC22A12 71/4885CYP2C19 48/4885EYA3 4188/4885 |
| US-20220112171-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | SLC10A1, UGT1A1, UGT1A3 | SLC22A12 71/4885CYP2C19 48/4885EYA3 4188/4885 |
| US-20230227419-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | SLC10A1, UGT1A1, UGT1A3 | SLC22A12 71/4885CYP2C19 48/4885EYA3 4188/4885 |
| US-20200148659-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | SLC10A1, UGT1A1, UGT1A3 | SLC22A12 71/4885CYP2C19 48/4885EYA3 4188/4885 |
| US-10239854-B2 | Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia | SLC10A1, UGT1A1, UGT1A3 | SLC22A12 71/4885CYP2C19 48/4885EYA3 4188/4885 |
| US-20190040030-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GOUT OR HYPERURICEMIA | SLC10A1, UGT1A1, UGT1A3 | SLC22A12 71/4885CYP2C19 48/4885EYA3 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.